Crossmark Global Holdings Inc. boosted its position in Edwards Lifesciences Corp (NYSE:EW) by 9.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,522 shares of the medical research company’s stock after purchasing an additional 2,265 shares during the period. Crossmark Global Holdings Inc.’s holdings in Edwards Lifesciences were worth $2,877,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Advisory Services Network LLC lifted its position in shares of Edwards Lifesciences by 0.9% during the 2nd quarter. Advisory Services Network LLC now owns 12,565 shares of the medical research company’s stock valued at $1,486,000 after acquiring an additional 112 shares during the period. Resources Investment Advisors Inc. lifted its position in shares of Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after acquiring an additional 465 shares during the period. Pacer Advisors Inc. lifted its position in shares of Edwards Lifesciences by 10.4% during the 3rd quarter. Pacer Advisors Inc. now owns 5,312 shares of the medical research company’s stock valued at $581,000 after acquiring an additional 499 shares during the period. Rodgers Brothers Inc. lifted its position in shares of Edwards Lifesciences by 1.5% during the 3rd quarter. Rodgers Brothers Inc. now owns 34,250 shares of the medical research company’s stock valued at $3,744,000 after acquiring an additional 500 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec lifted its position in shares of Edwards Lifesciences by 1.9% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 26,902 shares of the medical research company’s stock valued at $2,953,000 after acquiring an additional 500 shares during the period. Hedge funds and other institutional investors own 81.52% of the company’s stock.

EW has been the subject of a number of research reports. Cowen set a $135.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Sunday, December 10th. Evercore ISI initiated coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $140.00 price target for the company. Deutsche Bank reduced their price target on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research report on Thursday, October 26th. Barclays raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $135.00 in a research note on Thursday, January 4th. Finally, Canaccord Genuity reissued a “buy” rating and set a $137.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $141.15.

Edwards Lifesciences Corp (NYSE EW) opened at $126.27 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81. Edwards Lifesciences Corp has a 12 month low of $89.20 and a 12 month high of $138.48. The firm has a market cap of $26,721.26, a P/E ratio of 33.23, a PEG ratio of 1.86 and a beta of 0.63.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. The business had revenue of $888.50 million during the quarter, compared to analysts’ expectations of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The company’s revenue was up 15.7% on a year-over-year basis. During the same period last year, the company posted $0.75 EPS. research analysts predict that Edwards Lifesciences Corp will post 4.49 earnings per share for the current year.

Edwards Lifesciences announced that its board has approved a stock buyback program on Thursday, December 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

In other Edwards Lifesciences news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $104.76, for a total value of $1,986,249.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert W.A. Sellers sold 12,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $131.03, for a total transaction of $1,574,980.60. The disclosure for this sale can be found here. Insiders sold a total of 175,940 shares of company stock valued at $20,049,578 over the last ninety days. 2.13% of the stock is owned by corporate insiders.

WARNING: “Edwards Lifesciences Corp (EW) Position Raised by Crossmark Global Holdings Inc.” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://theolympiareport.com/2018/02/11/edwards-lifesciences-corp-ew-position-raised-by-crossmark-global-holdings-inc.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.